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Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer
therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor
treatment efficacy of Plk1 inhibitors. Furthermore, the Plk1 enzyme is expressed only in dividing cells and is a major
regulator of the cell cycle. It controls entry into mitosis and regulates the spindle checkpoint. The expression of Plk1
in normal cells is not nearly as strong as that in cancer cells, which makes Plk1 a discriminating tartget for the
development of cancer-specific small molecule drugs. RNA interference experiments in vitro and in vivo have
indicated that downregulation of Plk1 expression represents an attractive concept for cancer therapy. Over the
years, a number of Plk1 inhibitors have been discovered. Many of these inhibitors are substances that compete with
ATP for the substrate binding site. The ATP-competitive inhibitor BI 6727 is currently being clinically tested in
cancer patients. Another drug in development, poloxin, is the first Polo-box domain inhibitor of Plk1. This
compound is a derivative of the natural product, thymoquinone, derived from Nigella sativa. A novel and promising
strategy is to synthesize bifunctional inhibitors that combine the high binding affinity of ATP inhibitors with the
specificity of competitive inhibitors.
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Polo-like kinase 1 (Plk1) plays a critical role in cell div-
ision and represents a promising target for cancer ther-
apy. Several small molecule inhibitors of polo-like kinase
1 have been described. In the present review, we focus
on the biology of the Plk1 enzyme and the significance
of small molecule inhibitors as novel candidates for can-
cer therapy. Polo-like kinases are serine-threonine pro-
tein kinases. There are four different polo-like kinases
(Plk 1-4), of which Plk1 is the best studied. All Plks con-
sist of an amino-terminal catalytic kinase domain, which
is responsible for ATP-binding and enzyme activation,
and a carboxy-terminal polo box domain (PBD). The
PBD is involved in phosphopeptide binding and consists
of either one (in Plk 4) or two sequence motifs (in Plk 1,
Plk 2, and Plk 3) which each consist of 80 residues [1].
Phosphopeptides bind to the two motif-PBDs at the con-
sensus sequence S-pS/pT-P/X [2]. The PBDs of the four
Plks are similar, but not identical and have different
binding affinities. Plk1 and Plk 2 share the most similar* Correspondence: efferth@uni-mainz.de
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distribution, and reproduction in any mediumPBDs, whereas Plk4’s PBD is most dissimilar. Because
the Plk4 PBD consists of only one motif, it does not
form a binding pocket as the other Plks do [1,3]. Plk1
consists of 603 amino acids [4].The molecular biology of polo-like kinase 1
Structure of polo-like kinases
Plks possess a conserved catalytic kinase domain, which
consists of two lobes, each composed of a polypeptide
chain. A hinge region connects these two lobes allowing
their rotation. ATP molecules can bind at the gap be-
tween the two polypeptide chains. The binding pocket
structure is highly conserved among all Plks. In general,
all protein kinases reveal similar ATP-binding pockets,
which may pose problems in developing highly specific
kinase inhibitors [1,3].Function of Plk1
Protein kinases are important for a multitude of cellular
signal transduction reactions and are, therefore, subject
to strong regulation. They can be activated or inactated
by interaction with other proteins, peptides, or small
molecules or by translocation in the cell. Protein kinases
modify the activity of other proteins by phosphorylation.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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of the γ-phosphate from a donor molecule (ATP) to al-
coholic (serine, threonine) or phenolic (tyrosine) amino
acids, which bear a free hydroxyl group. Plk1 phosphory-
lates serine and threonine [5,6].
During mitosis, Plk1 binds and phosphorylates mul-
tiple proteins and hence plays a crucial role in cell pro-
liferation. It is therefore not surprising that Plk1 is only
expressed in dividing cells. During cell cycle progression,
fluctuations of Plk1 expression and activity can be
detected. The highest Plk1 levels can be observed during
the late G2 and M phases of the cell cycle. Furthermore,
Plk1’s cellular localization changes in the course of
mitosis [7].
Plk1 is involved in the activation of cyclin B1 and
Cdc25C, and thereby triggers entry of the cell into mi-
tosis. Furthermore, Plk1 plays a role in the maturation of
centromers, the formation and maintenance of the bipo-
lar spindle, the spindle checkpoint, exit from mitosis,
and cytokinesis. During interphase and prophase, Plk1 is
localized to the centrosome. In prometaphase and meta-
phase, it can be detected at the kinetochore and at the
spindle poles. During anaphase and telophase, Plk1 is
displaced to the central spindles [7].
In addition to promoting proliferation of healthy cells,
Plk1 also plays an important role in cancer development.
If Plk1 harbors mutations and is overexpressed, the mi-
totic cell cycle checkpoint is affected. Several cell cycle
checkpoints maintain genomic stability in normal cells,
including the G1, G2/M- and spindle checkpoints. Upon
DNA damage or other cellular injury, the cell cycle is
normaly arrested to allow for either damage repair or for
induction of apoptosis, if the extent of damage exceeds
that which the cell can repair. In cancer cells, cell cycle
arrest can be overridden due to defective checkpoints.
Frequently, checkpoints are bypassed by overexpression
of mitotic kinases involved in the control of the check-
points. As a consequence, proper cell division is no
longer guaranteed. Faulty chromosomal alignment and
distribution can occur, leading to aneuploidy. This is a
typical phenomenon in cancer cells. After DNA damage,
Plk1 activity allows cells in G2/M arrest to re-enter mi-
tosis by activating cyclin-dependent kinase 1 (Cdk1).
Prognostic value of Plk1 in clinical tumors
Compared to normal tissues, Plk1 is overexpressed in
many cancers, e.g. breast cancer, ovarian carcinoma colo-
rectal carcinoma, uterine cancer, skin cancer, stomach
cancer, and others. To estimate whether or not PLK1 ex-
pression is of prognostic value, we have summarized the
literature on this topic in Table 1.
Whereas most studies used immunohistochemistry to
analyze Plk1 expression, a few studies also used RT-PCR
to measure mRNA of Plk1 in human tumor samples.This difference is of interest becuase it has long been a
matter of discussion which methods are most suitable
for clinical routine diagnosis of molecular markers [27].
Despite the limitations of immunohistochemical detec-
tion of protein expression, this technique is often used
for practical reasons to investigate formalin-fixed and
paraffin-embedded tumor biopsies, which are the most
frequently used samples in pathology laboratories.
Table 1 demonstrates that Plk1 expression correlates
with clinicopathological parameters such as stage, grade,
metastasis, and survival time of patients. This indicates
that Plk1 may serve as valuable marker for prognosis of
treatment outcome and survival time.
Plk1 inhibitors
Approaches for the design of specific Plk1 inhibitors
Protein kinases have garnered great interest as thera-
peutic targets because they are involved in numerous
diseases including inflammatory, neurological, and neo-
plastic diseases [28]. In malignant cells, signal transduc-
tion is often dysregulated due to mutated-activated
protein kinases. The elucidation of the structure and
function of cell cycle regulators is critically important
for the development of target-specific therapeutic inhibi-
tors. In addition to being therapeutically relevant, kinase
inhibitors may also serve as biochemical tools to explore
signal transduction processes in experimental models.
Since Plk1 is overexpressed in many cancers, it repre-
sents an interesting target molecule for the development
of specific inhibitors to selectively treat cancer while
avoiding toxicity towards normal tissues [28,29].
Inhibition of Plk1 gene expression
There are several possibilities for suppressing Plk1 ex-
pression at the translation level. One mechanism with
therapeutic implications is the naturally occurring
process of RNA interference (RNAi), which is triggered
by double stranded RNA. RNAi leads to suppressed ex-
pression of genes with complementary sequences. RNA
fragments of about 21 nucleotides, called small interfer-
ing RNAs (siRNA), can be enzymatically cleaved into
single strands of RNA by an enzyme complex known
as RNA-induced silencing complex (RISC). The single-
stranded RNA fragments bind to complementary mRNA
resulting in its degradation. For the specific inhibition of
Plk1, siRNAs complementary to PLK1 mRNA have been
described that degrade PLK1 mRNA and downregulate
Plk1 protein levels [28].
Furthermore, PLK1 gene expression can be downregu-
lated by single-stranded DNA antisense oligonucleotides.
These antisense oligos bind to the complementary
mRNA and thereby prevent translation of PLK1 [28].
Inhibition of Plk1 by RNA interference in cancer
cells in vitro resulted in mitotic arrest and subsequent
Table 1 Role of Plk1 as prognostic marker in clinical tumors
Tumor type Number of
tumors
Method Result Reference
colorectal cancer 78 immunohistochemistry expression in tumors higher than in normal tissues [8]
significant correlations with invasion and Duke’s stage
advanced rectal cancer 76 immunohistochemistry significant correlations with tumor regression [9]
20 mRNA microarray and long-term clinical outcome
colorectal carcinoma 56 immunohistochemistry expression in tumors higher than in normal tissues [10]
significant correlations with Duke’s stage, tumor size,
invasion, and lymph node metastasis
gastric adenocarcinoma 208 immunohistochemistry expression in tumors higher than in normal tissues [11]
RT-PCR
gastric adenocarcinoma 160 immunohistochemistry prognostic factor for poor survival time [12]
RT-PCR
gastric adenocarcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues [13]
significant correlations with stage, nodal status and diffuse
growth pattern, no correlation to lymph node metastasis
hepatocellular carcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues, [14]
111 RT-PCR significant correlations to venous invasion, tumor nodules
and Edmondson grade, prognostic factor for poor survival time
hepatoblastoma 74 RT-PCR expression in tumors higher than in normal tissues [15]
non-small cell lung 100 immunohistochemistry expression in tumors higher than in normal tissues [16]
cancer significant correlations with stage, grade and lymph
node metastasis
melanoma 36 significant correlation with metastasis
astrocytic tumors immunohistochemistry significant correlation with grade of anaplasia [17]
non-Hodgkin lymphoma 66 immunohistochemistry prognostic factor for poor survival time [18]
non-Hodgkin lymphoma 118 immunohistochemistry significant correlations with grade,
prognostic factor for poor survival time
cutaneous T-cell 49 immunohistochemistry expression in tumors higher than in patch and [19]
lymphoma plaque-stage lesions
muliple myeloma 188 immunohistochemistry prognostic factor for poor survival time [20]
breast carcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues [21]
no correlation with 10 year survival time
breast carcinoma 3093 immunohistochemistry no correlation with 10 year survival time [22]
ovarian tumors 17 immunohistochemistry significant correlation with grade [23]
ovarian tumors 107 immunohistochemistry expression in high malignant tumors than in low [24]
malignant tumors, prognostic factor for poor survival time
endometrial tumors 20 immunohistochemistry significant correlation with grade [25]
cervical carcinoma 36 immunohistochemistry significant correlation with tumor size [26]
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apparently have no back-up mechanism to bypass Plk1
inhibition. This makes Plk1 a promising target for
small molecule drug development, as Plk1 RNAi is dif-
ficult to acheive in vivo. Nevertheless, Strebhardt et al.
[3] were able to inhibit PLK1 expression by RNAi both
in vitro and in vivo, and demonstrated a specific kill-
ing of cancer cells while normal cells survived. The
reasons for this result are still not completely under-
stood. It is thought that PLK1 siRNA might not only
partially inhibit Plk, and that the residual enzyme ac-
tivity is sufficient for normal cells to survive. Another
explanation could be that normal cells activate alterna-
tive pathways to respond to siRNA-mediated challenge,
allowing them to survive. This may be a siRNA-
specific phenomenon, since chemical small moleculessuch as BI 2536 or Poloxin inhibited both proliferating
normal and malignant cells in a consistent manner
in vitro [2]. Overall, the development of therapeutic
siRNAs to inhibit PLK1 gene expression level may be
conceivable.
Functional Plk1 inhibitors
A detailed knowledge of the exact structural configur-
ation and functional operation of Plk1 is a prerequisite
for the synthesis of highly specific polo-like kinase 1
inhibitors. In this context, the phosphorylation reactions
play a crucial role, because this is the starting point for
the design of specific inhibitors. Different inhibitors can
be distinguished depending on their mode of action:
inhibitors can compete with either ATP or the substrate
or with both ATP and the substrate of Plk1 [5].
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target for the synthesis of kinase inhibitors, the first
designed Plk1 inhibitors were ATP analogues that block
the ATP binding pocket and thereby prevent access to
ATP. For the design of novel inhibitor scaffolds,
computer-based methods such as pharmacophore mod-
eling and virtual screening are now used. After identifi-
cation of candidate compounds in large chemical
libraries, wet lab experiments must be used to verify the
binding between the compounds and Plk1. Chemical
scaffolds may serve as lead compounds which can be
subsequently optimized by derivatization to acheive
more specific binding to Plk1. In this context, the Plk1
amino acids Arg136 and Leu13 are essential for inhibitor
binding, as in the case of BI 2536 [3]. Nevertheless, inhi-
bitors designed to bind to Plk1 are also capable of bind-
ing non-specifically to other protein kinases, because all
protein kinases share a similar amino acid sequence and
highly conserved structure in their ATP-binding pocket.
The probability is high that ATP-competitive Plk1 inhi-
bitors will also bind to other members of the PLK family
(with the exception of Plk4, which is dissimilar to the
other Plks). Therefore, it is a non-trivial task to develop
Plk1-specific inhibitors. For example, the Plk1 inhibitors
PHA-680626 and BI 2536 do not sufficiently distinguish
between Plk1, Plk2, and Plk3 and interact with all three.
Second generation inhibitors such as ZK-thiazolidinone,
NMS-P937, GSK461364, or BI 2767 are believed to be
more specific [3].
To increase the specificity of Plk1 inhibition, sub-
stances binding to the PBD and competing with natural
Plk1 substrates have been developed. These compounds
are able to block protein-protein interactions and con-
sist of modified peptides, which contain consensus
sequences for the corresponding substrates. As proof-
of-principle, it was shown for protein kinase A (PKA)
that peptide analogs with longer consensus sequences
have a greater inhibitory effect than peptide analogs
with shorter substrate consensus sequences [30].
Plks are the only protein kinases that cotain PBDs.
Therefore, it has been attempted to increase the speci-
ficity of inhibitors by using sequences complementary
to the PBD. The PBD binds with high affinity peptides
containing the consensus sequence S-pS/pT-P/X. The
first substrate-competitive Plk1 inhibitor, which binds
specifically to the PBD, was discovered using a recently
developed fluorescence polarization assay. First, a fluoro-
phore-coupled peptide binds with high affinity to the
PBD of Plk1. Next, a chemical library of low molecular
weight compounds was tested. These compounds inter-
act with the Plk1 PBD and thus compete with the
fluoropore-coupled peptide for access to the kinase,
which can be measured by fluorescence polarization. The
fluorescence polarization is higher when the labeledpeptide is bound to the PBD of Plk1. The polarization
is reduced upon displacement of the fluorescing pep-
tide by an inhibitor. Applying this technology resulted
in the discovery of synthetic poloxin as well as the
natural product, thymoquinone [31]. Other inhibitors
that bind to the PBD of Plk1 are purpurogallin and
poloxipan [3].
As a next step to increase specificity, bifunctional inhi-
bitors have been developed, which inhibit binding of
both ATP and substrate via two domains connected by a
linker. These compounds compete simultaneously with
ATP and the peptide or protein substrate for their re-
spective binding sites. The particular advantage of these
bifunctional compounds is that they combine the high
affinity of the ATP analogue, and the specificity of the
substrate analogue. Ideally, such inhibitors should bind
with high affinity to the target enzyme and simultan-
eously be able to discriminate between closely related
specific protein kinases. The structure and the length of
the linkage between the ATP and substrate analogues
can greatly affect the efficiency of bifunctional inhibitors.
As yet, bifunctional Plk1 inhibitors have not been devel-
oped [5,32].
Another type of inhibitor interacts with the kinase
substrate to prevent phosphorylation. Since the inhibitor
does not directly target the protein kinase itself in this
approach, it is quite different from the other known kin-
ase inhibitors. Such inhibitors for Plk1 are not yet
known [5,33].
The challenge to identify Plk1 inhibitors
The aim is to find substances that are able to inhibit
Plk1-mediated phosphorylation of proteins by specific-
ally and binding with high affinity to Plk1. Protein
kinases are one of the largest protein families. The
human proteome contains more than 2,000 different
protein kinases of which Plk1 is just one [34]. This illus-
trates the magnitude of the task of identifying a Plk1
specific inhibitor; finding a compound that only inhibits
one particular kinase is quite difficult, especially when
there are so many structurally similar enzymes present
in the cell.
Furthermore, ATP is used by all protein kinases as a
donor molecule for γ-phosphate. The sequence and
structure of the binding site is highly conserved, and
therefore similar in all protein kinases, to enable ATP
binding to the enzyme. This complicates the specific in-
hibition of Plk1. Another problem is the intracellular
ATP concentrations, which are in the millimolar range.
The Km values of protein kinases, however, are signifi-
cantly lower, i.e. about one-thousandth of the intracellu-
lar ATP concentrations. Therefore, there is a saturation
of ATP-binding protein kinases under physiological con-
ditions. A novel ATP analogue must meet two criteria. It
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ase and its binding affinity has to be high enough to dis-
place the surplus ATP and the donor molecule [5].
Furthermore, protein kinases phosphorylate only
certain amino acid residues. One system of kinase
classification is based on the nature of the residue phos-
phorylated, i.e. some phosphorylate tyrosine and serine
while others are solely threonine kinases. Therefore, the
amino acid sequence of the substrate phosphorylation
site is highly conserved. Protein kinases that phosphor-
ylate the same amino acid residues show highly similar
sequences, which complicates the design of specific
binding inhibitors. The more closely related the pro-
teins, the more similar are their binding sites. Since
Plk1 through Plk3 (but not Plk4) contain a two-motif-
PBD, they share very similar (but not identical) amino
acid sequences for the substrate binding sites. The chal-
lenge is to design a non-phosphorylatable peptide
analogue that specifically binds to the high affinity and
substrate binding site of Plk1 [5].
Examples of Plk1 inhibitors
BI 6727
BI 6727 represents an ATP-competing kinase inhibitor
belonging to a class called dihydropteridinones. It binds
to the hinge region between the NH2-terminal end and
the COOH-terminal end of the catalytic kinase domain.
The binding takes place via two hydrogen bonds from
the interior of the backbone of the NH- and carbonyl
groups of Cys133. Thereby, BI 6727 occupies the ATP
binding site of Plk1, which leads to a catalytical inactiva-
tion. BI 6727 stops cell division and the arrests the cell
cycle in the G2/M phase, which is followed by apoptosis
[29] in vitro and in vivo. This inhibitor was tested on 50
patients suffering from advanced or metastasized solid
tumors in a clinical Phase I trial. Thrombocytopenia and
neutropenia occurred as side effects [3]. It has been
shown that BI 6727 inhibits Plk2 as well as Plk1, indicat-
ing that it is not the optimal candidate drug for specific
Plk1 inhibition.
Poloxin
Poloxin is a synthetical derivative of the phytochemical
thymoquinone. It was the first small molecule identified
to block Plk1 by specifically binding to the PBD. The
identification was based on the screening of a chemical
library by means of the above described fluorescence
polarization assay [2]. Poloxin is the first non-peptide
Plk1 inhibitor, and it prevents protein-protein interac-
tions of Plk1’s two PBDS. The lead compound, thymo-
quinone, is a biologically active component of the seed
oil of Nigella sativa volatile. Thymoquinone is known
to exert anti-inflammatory, anti-oxidative and anti-
neoplastic activities [3] and strongly inhibits Plk1, butalso other protein kinases such as Plk2, Plk3, Chk2,
Pin1 and STAT3. For this reason, the more specific de-
rivative, poloxin, was synthesized. However, poloxin is
less active than the natural lead compound. Therefore,
its inhibitory effect towards the PBD of Plk1 was lower
[31]. Poloxin reduced the localization of Plk1 at the kin-
etochore and the centrosomes, induced defects in
chromosome arrangements, arrested cells in prometa-
phase, and induced apoptosis [2].
GW843682X
The substance GW843682X was discovered during
chemical optimization of a thiophene. Thiophenes were
hypothesized to serve as chemical scaffolds for inhibitors
because they are known to have a good inhibitory effect
on Plk1. GW843682X is a competitive ATP inhibitor,
which occupies the ATP binding site and inhibits the
kinase activity. It arrested various cancer cell lines with
aberrant Plk1 expression in the G2/M cell cycle phase
and induced apoptosis. Furthermore, the anti-cancer ef-
fect of this compound was also demonstated in vivo. A
clinical Phase I trial with patients suffering from
advanced solid tumors was performed to determine the
maximum tolerated dose and to perform pharma-
cokinetic analysis. The dose-limiting side effects of
GW843682X include sepsis, pulmonary embolism, and
neutropenia. GW843682X revealed 400-fold greater in-
hibitory activity towards Plk1 than towards Plk2 and
Plk3 [3].
Conclusion
PLK1 represents an exquisite prognostic marker and tar-
get for cancer therapy because of its strong expression
in cancer but weak expression in normal tissues. A num-
ber of PLK1 inhibitors have been discovered during the
past years, some of which are being tested in clinical
trials. Once PLK1 inhibitors are clinically approved, they
will represent an attractive novel strategy to improving
treatment outcome.
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